isolated protein, isolated nucleic acid molecule, recombinant vector, host cell, method of producing a hybrid actriib protein, pharmaceutical composition, methods of treating myostatin or activin-related disorders, muscle wasting disease, disease cardiovascular disease, metabolic disorders, cancer cells, kidney disease, inflammatory / autoimmune disease, fibrosis disease, anemia, pain, aging condition, bone disorders, muscle wasting or metabolic disorder or fibrotic or inflammatory or activin-related in individuals, and a method of inducing stem cell growth for tissue repair or organ regenerat
The present disclosure relates to novel hybrid soluble actriib-ecd polypeptides that fully retain binding affinity for myostatin and activin a, but demonstrate significantly reduced binding to bmps, especially bmp-9. The novel compositions described herein can be used to prepare novel hybrid actriib ligand-blocking proteins, which can be used for modulating muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue growth to counteract muscle wasting, loss bone, anemia, inflammation and fibrosis in a therapeutically significant manner. Because these new-generation myostatin / activin inhibitors are safer and more effective molecules than currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.a presente revelação refere-se a novos polipeptídeos actriib-ecd solúveis híbridos que retêm totalmente a afinidade de ligação com miostatina e ativina a, mas demonstram ligação significativamente reduzida a bmps, especialmente bmp-9. as novas composições descritas aqui podem ser usadas para preparar novas proteínas bloqueadoras de ligante actriib híbridas, que podem ser usadas para a modulação do crescimento de tecido muscular, ósseo, cartilaginoso, gorduroso, fibroblástico, sanguíneo e neuronal para neutralizar o desgaste dos músculos, perda óssea, anemia, inflamação e fibrose de uma maneira terapeuticamente significativa. visto que estes novos inibidores de miostatina/ativina de nova geração são moléculas mais seguras e mais eficazes do que os inibidores de miostatina atualmente disponíveis, eles são úteis em uma ampla variedade de indicações clínicas.
